GLENMARK
532296Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals Inc., USA launches Calcium Gluconate Injection USP, 1,000 mg/10 mL (100 mg/mL), 5,000 mg/50 mL (100 mg/mL) Single-Dose Vials and 10,000 mg/100 mL (100 mg/mL) Pharmacy Bulk Pac...read more
Glenmark Pharmaceuticals Ltd. is a global pharmaceutical company headquartered in Mumbai, India, with a diversified presence across branded generics, specialty, and over-the-counter (OTC) segments. Established in 1977, Glenmark has built an extensive footprint across more than 80 countries, leveraging robust R&D capabilities to offer innovative and affordable healthcare solutions.
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals Inc., USA launches Calcium Gluconate Injection USP, 1,000 mg/10 mL (100 mg/mL), 5,000 mg/50 mL (100 mg/mL) Single-Dose Vials and 10,000 mg/100 mL (100 mg/mL) Pharmacy Bulk Package
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals receives U.S. FDA approval for Fluticasone Propionate Nasal Spray, 0.05 mg (50 mcg)/spray
Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Advertisement regarding the 48th Annual General Meeting ("AGM") to be held on Friday, September 11, 2026 at 2.00 p.m. through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM")
Letter To Shareholders Whose Email Address Are Not Registered Providing The Web Link Of Annual Report
Letter to Shareholders whose email address are not registered providing the web link of Annual Report
Business Responsibility and Sustainability Reporting (BRSR)
Please find attached Business Responsibility and Sustainability Reporting for Financial Year 2025-26
Reg. 34 (1) Annual Report.
Please find attached Notice convening the 48th Annual General Meeting and the Integrated Annual Report including BRSR for the Financial Year 2025-26.
Notice Of The 48Th Annual General Meeting For The Financial Year 2025-26
Please find attached Notice of 48th Annual General Meeting for the Financial Year 2025-26
Settlement Agreement - Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosures Requirements) Regulations, 2015
Settlement Agreement - Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Intimation of Allotment of shares under the Employee Stock Option Plan 2016
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst / Institutional Investor Meetings
Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Advertisement regarding the 48th Annual General Meeting ("the AGM") to held through Video Conferencing ("VC")/ Other Audio-Visual Means ("OAVM")
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of the Earnings Call
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio recording of Q1 FY 2026-27 Earnings Call held on August 03, 2026
Glenmark Pharmaceuticals Ltd
About
Glenmark Pharmaceuticals Ltd. is a global pharmaceutical company headquartered in Mumbai, India, with a diversified presence across branded generics, specialty, and over-the-counter (OTC) segments. Established in 1977, Glenmark has built an extensive footprint across more than 80 countries, leveraging robust R&D capabilities to offer innovative and affordable healthcare solutions.
The company’s operations span key therapeutic areas such as dermatology, respiratory, oncology, and cardiology.
Glenmark's business is supported by state-of-the-art manufacturing facilities and a strong distribution network reaching both emerging and developed markets. The company maintains a focus on sustainable growth, patient-centric innovation, and compliance with global regulatory standards, underscoring its position as a trusted partner in the healthcare ecosystem.
Business Model & Strategy
Glenmark Pharmaceuticals generates revenue through the research, development, manufacturing, marketing, and distribution of branded generics and specialty pharmaceutical products. The company's strategy emphasizes geographical expansion, a diverse therapeutic portfolio, and investments in novel drug delivery systems. Significant revenue streams arise from the US, India, and key markets in Europe, Latin America, and the rest of the world.
Growth is driven by an increasing focus on specialty and complex generics, the launch of differentiated products, and partnerships for biosimilars and new chemical entities. Glenmark is also increasing investments in R&D to develop first-in-class and best-in-class assets in its core therapy areas, supporting its long-term aim to move up the pharmaceutical value chain.
Management Overview
9 MembersMr.GLENN SALDANHA
Executive Director-Chairperson related to Promoter-CEO-MDMrs.BLANCHE SALDANHA
Non-Executive - Non Independent DirectorMrs.CHERYLANN PINTO
Executive DirectorMs.SONA SAIRA RAMASASTRY
Non-Executive - Independent DirectorMr.DIPANKAR BHATTACHARJEE
Non-Executive - Independent DirectorMrs.VIJAYALAKSHMI RAJARAM IYER
Non-Executive - Independent DirectorMr.PRADEEP KUMAR SINHA
Non-Executive - Independent DirectorMr.ANURAG MANTRI
Executive DirectorHarishKuber
Company Secretary & Compliance OfficerAwards & Recognition
5 Awards- Featured in Forbes India’s 'India’s Super 50 Companies' (2022)
- Winner of CII National Quality Award (2023)
- Received 'Best Workplaces in Health & Wellness' recognition by ET Now (2024)
- Consistently rated for strong ESG performance in third-party sustainability ratings
- Recipient of several US FDA and EU certifications for manufacturing facilities
Market Information
Company Timeline
47+ Years of Excellence | 7 Major Milestones
Glenmark Pharmaceuticals founded by Gracias Saldanha in Mumbai, India.
Initial public offering (IPO) and listing on BSE and NSE.
Established Glenmark Generics Limited to focus on US and European generics markets.
Expanded global presence by entering the Latin American and CIS regions.
Filed first New Drug Application with the US FDA for a novel, innovative asthma therapy.
Strategic divestment of select non-core assets to strengthen focus on specialty pipeline.
Announced the launch of multiple complex generics and biosimilars targeting US and EU markets.
The Next Evolution
Contact Information
Registered Office
B2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road
Tel: 022-40189999 / 40189879,
Fax: 022-40189986 / 40189986,
Email: complianceofficer@glenmarkpharma.com
Website: glenmarkpharma.com
Corporate Actions
13| Purpose | Ex Date | Record Date | BC Start | BC End |
|---|---|---|---|---|
Final Dividend ₹2.50 per share | 31 Aug 2026 Monday | 31 Aug 2026 Monday | - | - |
Interim Dividend ₹2.50 per share | 03 Oct 2025 Friday | 03 Oct 2025 Friday | - | - |
Final Dividend ₹2.50 per share | 15 Sep 2025 Monday | 15 Sep 2025 Monday | - | - |
Final Dividend ₹2.50 per share | 13 Sep 2024 Friday | - | 17 Sep 2024 Tuesday | 27 Sep 2024 Friday |
Final Dividend ₹2.50 per share | 18 Sep 2023 Monday | - | 19 Sep 2023 Tuesday | 29 Sep 2023 Friday |
Final Dividend ₹2.50 per share | 12 Sep 2022 Monday | - | 14 Sep 2022 Wednesday | 27 Sep 2022 Tuesday |
Final Dividend ₹2.50 per share | 08 Sep 2021 Wednesday | - | 10 Sep 2021 Friday | 24 Sep 2021 Friday |
Dividend ₹2.50 per share | 17 Sep 2020 Thursday | - | 19 Sep 2020 Saturday | 29 Sep 2020 Tuesday |
Dividend ₹2 per share | 19 Sep 2019 Thursday | - | 21 Sep 2019 Saturday | 27 Sep 2019 Friday |
Dividend ₹2 per share | 19 Sep 2018 Wednesday | - | 22 Sep 2018 Saturday | 28 Sep 2018 Friday |
Dividend ₹2 per share | 20 Sep 2017 Wednesday | - | 22 Sep 2017 Friday | 29 Sep 2017 Friday |
Dividend ₹2 per share | 03 Aug 2016 Wednesday | - | 05 Aug 2016 Friday | 12 Aug 2016 Friday |
Dividend ₹2 per share | 10 Sep 2015 Thursday | - | 14 Sep 2015 Monday | 22 Sep 2015 Tuesday |
₹69,280 Cr.
₹2,464
₹2,538 / 1,793
38.53
₹372.49
6.59
₹63.71
₹1.00
0.31 %
Manage Ratio
FINANCIALS
| Annual Results | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income | - | - | - | 10,074 | 10,801 | 10,994 | 12,472 | 13,307 | 12,653 | 13,435 | 17,443 | 18,236 |
| Expenses | - | - | - | 8,940 | 9,737 | 9,656 | 10,769 | 11,673 | 11,716 | 11,663 | 13,192 | 13,761 |
| Profit | - | - | - | 925 | 776 | 970 | 994 | 377 | -1,433.52 | 1,047 | 1,362 | 1,798 |
| Tax | - | - | - | 376 | 320 | 412 | 448 | 491 | 1,867 | 352 | 623 | 735 |
| EPS | - | - | - | 33 | 28 | 34 | 33 | 11 | -67.30 | 37 | 48 | 17.11 |
| Ratios | - |
Cash Flow
Consolidated Figures in Rs. Crores
| Annual Balance Sheet | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | - |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | - | - | - | 13,289 | 14,685 | 15,604 | 17,083 | 19,372 | 14,359 | 16,050 | 19,908 | - |
| Equity And Liabilities | - | - | - | 13,289 | 14,685 | 15,604 | 17,083 | 19,372 | 14,359 | 16,050 | 19,908 | - |
Shareholding Pattern
Numbers in Percentages
| Quarterly SHP Announcement Date | Mar 2016 12 Apr '16 | Mar 2017 31 Mar '17 | Mar 2018 31 Mar '18 | Mar 2019 12 Apr '19 | Mar 2020 22 Apr '20 | Mar 2021 10 Apr '21 | Mar 2022 14 Apr '22 | Mar 2023 18 Apr '23 | Mar 2024 16 Apr '24 | Mar 2025 16 Apr '25 | Mar 2026 15 Apr '26 | - |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Goverments | - | - | - | - | - | - | - | 0.04% | 0.04% | 0.04% | - | - |
| Promoter And Promoter Group | - | - | - | 46.54% | 46.62% | 46.63% | 46.65% | 46.65% | 46.64% | 46.65% | 46.65% | - |
| Non Institutions | - | - | - | 13.90% | 18.12% | 18.38% | 18.27% | 20.45% | 18.58% | 15.56% | 13.68% | - |
| FII | - | - | - | - | - | - | - | 22.46% | 21.38% | 23.16% | 20.34% | - |
| DII | - | - | - | - | - | - | - | 10.41% | 13.36% | 14.60% | 19.29% | - |
| Total | - | - | - | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | - |
Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd. is a global pharmaceutical company headquartered in Mumbai, India, with a diversified presence across branded generics, specialty, and over-the-counter (OTC) segments. Established in 1977, Glenmark has built an extensive footprint across more than 80 countries, leveraging robust R&D capabilities to offer innovative and affordable healthcare solutions.
The company’s operations span key therapeutic areas such as dermatology, respiratory, oncology, and cardiology.
Glenmark's business is supported by state-of-the-art manufacturing facilities and a strong distribution network reaching both emerging and developed markets. The company maintains a focus on sustainable growth, patient-centric innovation, and compliance with global regulatory standards, underscoring its position as a trusted partner in the healthcare ecosystem.
Glenmark Pharmaceuticals generates revenue through the research, development, manufacturing, marketing, and distribution of branded generics and specialty pharmaceutical products. The company's strategy emphasizes geographical expansion, a diverse therapeutic portfolio, and investments in novel drug delivery systems. Significant revenue streams arise from the US, India, and key markets in Europe, Latin America, and the rest of the world.
Growth is driven by an increasing focus on specialty and complex generics, the launch of differentiated products, and partnerships for biosimilars and new chemical entities. Glenmark is also increasing investments in R&D to develop first-in-class and best-in-class assets in its core therapy areas, supporting its long-term aim to move up the pharmaceutical value chain.
Featured in Forbes India’s 'India’s Super 50 Companies' (2022)
Winner of CII National Quality Award (2023)
Received 'Best Workplaces in Health & Wellness' recognition by ET Now (2024)
Consistently rated for strong ESG performance in third-party sustainability ratings
Recipient of several US FDA and EU certifications for manufacturing facilities
Glenmark Pharmaceuticals founded by Gracias Saldanha in Mumbai, India.
Initial public offering (IPO) and listing on BSE and NSE.
Established Glenmark Generics Limited to focus on US and European generics markets.
Expanded global presence by entering the Latin American and CIS regions.
Filed first New Drug Application with the US FDA for a novel, innovative asthma therapy.
Strategic divestment of select non-core assets to strengthen focus on specialty pipeline.
Announced the launch of multiple complex generics and biosimilars targeting US and EU markets.
Peer Comparison
| S.No. | Company Name | CMP (₹) | Market Cap (₹ Cr) | Div Yld (%) | NP Qtr (₹ Cr) | Qtr Profit Var (%) | Sales Qtr (₹ Cr) | Qtr Sales Var (%) | ROCE (%) | ROE (%) | Book Value (₹) | EPS TTM (₹) | TTMPE Ratio (₹) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Coming Soon
Heatmap View
Premium Feature| Company | CMP (₹) | MCap (₹ Cr) | EPS TTM (₹) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Financial Ratios
Premium Feature| Company Name | P/E (TTM) | EPS (₹) | D/E | NPM | GPM | ROE (%) | ROCE (%) | P/B | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Coming Soon